China NMPA Product Recall - Paroxetine hydrochloride tablets (20mg), paroxetine hydrochloride enteric-coated extended-release tablets (12.5mg), paroxetine hydrochloride enteric-coated extended-release tablets (25mg)
China NMPA product recall for Paroxetine hydrochloride tablets (20mg), paroxetine hydrochloride enteric-coated extended-release tablets (12.5mg), paroxetine hydrochloride enteric-coated extended-release tablets (25mg) by GlaxoSmithKline (Tianjin) Pharmaceutical Co., Ltd., GlaxoSmithKline Inc. (Canada) published May 13, 2014. Recall level: Level 3 Recall. GlaxoSmithKline (GSK) initiated a voluntary global recall of specific batches of paroxetine hydrochl
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA product recall for Paroxetine hydrochloride tablets (20mg), paroxetine hydrochloride enteric-coated extended-release tablets (12.5mg), paroxetine hydrochloride enteric-coated extended-release tablets (25mg) by GlaxoSmithKline (Tianjin) Pharmaceutical Co., Ltd., GlaxoSmithKline Inc. (Canada) published May 13, 2014. Recall level: Level 3 Recall. GlaxoSmithKline (GSK) initiated a voluntary global recall of specific batches of paroxetine hydrochl
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox